Table 1 Patient characteristics
HDR-ISBT+IMRT | LDR-ISBT+IMRT | p value | |
|---|---|---|---|
n(%) | n(%) | ||
Age[years], median(range) | 67.8 (54.5-81.4) | 65.8 (52.6-78.8) | 0.498 |
Stage | 0.867 | ||
■T1b | 1 (4.5) | 1 (6.3) | |
■T1c | 11 (50) | 9 (56.2) | |
■T2a | 2 (9.1) | 1 (6.3) | |
■T2b | 2 (9.1) | 3 (18.8) | |
■T2c | 2 (9.1) | 1 (6.3) | |
■T3a | 2 (9.1) | 1 (6.3) | |
■T3b | 2 (9.1) | 0 (0) | |
Initial PSA | 0.061 | ||
■<10 | 7 (31.8) | 8 (50) | |
■ 10-20 | 8 (36.4) | 7 (43.7) | |
■>20 | 7 (31.8) | 1 (6.3) | |
Gleason Score | 0.029* | ||
■<7 | 0 (0) | 0 (0) | |
■7 | 17 (77.3) | 16 (100) | |
■>7 | 5 (22.7) | 0 (0) | |
Risk grouping (NCCN classification) | 0.031* | ||
■ Low | 0 (0) | 0 (0) | |
■ Intermediate | 12 (54.5) | 14 (87.5) | |
■ High | 10 (45.5) | 2 (12.5) | |
Baseline t-IPSS, median(range) | 8.3 (1.0-23.0) | 6.75 (1.5-23.0) | 0.982 |
ADT | 10 (45.5) | 3 (18.8) | 0.087 |
Folow-up [days], median(range) | 1048.5 (409–2199) | 1070.5 (617–2199) | 0.321 |
Prostate volume [cc], median(range) | 40.8(17.5-94.5) | 33.1(13.6-73.8) | 0.12 |